Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.
Boshuizen J, Vredevoogd DW, Krijgsman O, Ligtenberg MA, Blankenstein S, de Bruijn B, Frederick DT, Kenski JCN, Parren M, Brüggemann M, Madu MF, Rozeman EA, Song JY, Horlings HM, Blank CU, van Akkooi ACJ, Flaherty KT, Boland GM, Peeper DS. Boshuizen J, et al. Among authors: blankenstein s. Nat Commun. 2020 Aug 7;11(1):3946. doi: 10.1038/s41467-020-17739-8. Nat Commun. 2020. PMID: 32770055 Free PMC article.
Adjuvant systemic therapy in high-risk melanoma.
Blankenstein SA, van Akkooi ACJ. Blankenstein SA, et al. Melanoma Res. 2019 Aug;29(4):358-364. doi: 10.1097/CMR.0000000000000604. Melanoma Res. 2019. PMID: 30896556 Review.
Broadening indications for neoadjuvant immunotherapy.
Blankenstein SA, van Akkooi ACJ. Blankenstein SA, et al. Br J Dermatol. 2020 Sep;183(3):421-422. doi: 10.1111/bjd.18873. Epub 2020 Feb 3. Br J Dermatol. 2020. PMID: 32017031 No abstract available.
18F-FDG PET/CT During Neoadjuvant Targeted Therapy in Prior Unresectable Stage III Melanoma Patients: Can (Early) Metabolic Imaging Predict Histopathologic Response or Recurrence?
van der Hiel B, Blankenstein SA, Aalbersberg EA, Wondergem M, Stokkel MPM, van de Wiel BA, Klop WMC, van Akkooi ACJ, Haanen JB. van der Hiel B, et al. Among authors: blankenstein sa. Clin Nucl Med. 2022 Jul 1;47(7):583-589. doi: 10.1097/RLU.0000000000004217. Epub 2022 Apr 22. Clin Nucl Med. 2022. PMID: 35452004
Surgery for Metastatic Melanoma: an Evolving Concept.
Testori AAE, Blankenstein SA, van Akkooi ACJ. Testori AAE, et al. Curr Oncol Rep. 2019 Nov 6;21(11):98. doi: 10.1007/s11912-019-0847-6. Curr Oncol Rep. 2019. PMID: 31696407 Review.
Primary Melanoma: from History to Actual Debates.
Testori AAE, Blankenstein SA, van Akkooi ACJ. Testori AAE, et al. Among authors: blankenstein sa. Curr Oncol Rep. 2019 Dec 19;21(12):112. doi: 10.1007/s11912-019-0843-x. Curr Oncol Rep. 2019. PMID: 31858280 Review.
Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR: A Prospective, Single-arm, Open-label Phase II Trial.
Blankenstein SA, Rohaan MW, Klop WMC, van der Hiel B, van de Wiel BA, Lahaye MJ, Adriaansz S, Sikorska K, van Tinteren H, Sari A, Grijpink-Ongering LG, van Houdt WJ, Wouters MWJM, Blank CU, Wilgenhof S, van Thienen JV, van Akkooi ACJ, Haanen JBAG. Blankenstein SA, et al. Ann Surg. 2021 Aug 1;274(2):383-389. doi: 10.1097/SLA.0000000000004893. Ann Surg. 2021. PMID: 33843797 Clinical Trial.
Postoperative radiotherapy in stage I-III Merkel cell carcinoma.
Levy S, Blankenstein SA, Grünhagen DJ, Jalving M, Hamming-Vrieze O, Been LB, Tans L, van Akkooi ACJ, Tesselaar MET. Levy S, et al. Among authors: blankenstein sa. Radiother Oncol. 2022 Jan;166:203-211. doi: 10.1016/j.radonc.2021.11.017. Epub 2021 Nov 25. Radiother Oncol. 2022. PMID: 34838887 Free article.
15 results